Most recently, Biller has worked for Novartis as the vice president and head of global discovery chemistry at the Novartis Institutes for BioMedical Research (NIBR).
Befor joining Novartis, Biller was the vice president of Pharmaceutical Candidate Optimisation at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute, and executive director of Drug Discovery Chemistry for the BMS research site in Lawrenceville, NJ.
Agios Pharma, CEO David Schenkein said that Scott’s breadth of experience and record of leadership in the industry makes him the ideal candidate to shape and lead our research initiatives.